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Epithelial-mesenchymal transition (EMT) is a process by which cancer cells acquire
mesenchymal properties, such as induction ofvimentin, while epithelial-associated genes
like E-cadherin are lost. This enables the cells to be more metastatic. Factors that can
induce EMT include growth factors like transforming growth factor -P (TGF-P) and
epidermal growth factor (EGF), and transcription factors like Snail. Snail-induced EMT
promotes migration and invasion and we hypothesized that this may be mediated by
urokinase (uPA) and its receptor (uPAR) activities. LNCaP, 22Rvl and ARCaP human
prostate cancer (CaP) cells stably transfected with constitutively active Snail displayed
increased cell invasion as compared to the empty vector control (Neo). Superarray
analysis revealed an up-regulation in uPA and uPAR RNA expression in Snail-
transfected ARCaP cells as compared to Neo control. Next, the protein expression levels
of Snail, uPA, and uPAR were measured by western blot analysis in various prostate
cancer cell lines which showed that overexpression of Snail increased uPA and uPAR
protein levels. The activity ofuPA in conditioned media was measured using an ELISA
assay which revealed that uPA activity was elevated in LNCaP, 22Rvl and ARCaP cells
overexpressing Snail. Additionally, transient silencing ofuPAR in ARCaP cells
overexpressing Snail using siRNA resulted in abrogation of Snail-mediated invasion.
Snail overexpression was associated with increased ERK activity and antagonism of this
activity with MAPK inhibitor, UO126, inhibited cell invasion and decreased uPA
activity. Therefore, Snail-mediated cell invasion in human prostate cancer cells may
occur via the regulation ofuPA/ uPAR and the MAPK signaling pathways.
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Prostate cancer (CaP) is the most commonly diagnosed malignancy in the United
States, with most cases occurring in men over the age of 55 (1). In 2013, about 238,590
new cases ofCaP will be diagnosed and about 29,720 men will die of CaP in the United
States alone (1). The incidence and mortality rates ofCaP in African American men as
compared to Caucasian males are very alarming. This year alone, African American men
will account for 37% ofthe newly diagnosed incidence and have a mortality rate 2.4
times higher than Caucasian men. Unfortunately, there is no single cause for these
inequalities but may be due to the following: genetic variations, diets, exposure to
environmental factors, and socioeconomic disparities. Tumors that are detected early via
testing serum prostate-specific antigen (PSA) or digital rectal examination (DRE) can be
effectively treated by prostatectomy or radiation therapy (2). About 30% oftreated
patients suffer relapse and progress to hormone refractory prostate cancer (HRPC), which
no longer responds to androgen ablation whereas early CaP growth is androgen
dependent. At that stage, there is no curative therapy available for metastatic CaP (3, 4).
Metastasis is a complex process by which cancer cells leave the primary tumor and
migrate to a secondary site where they recolonize. It consists of multiple steps that are
interconnected including: invasion, migration, intravasation, extravasation, and
recolonization (5, 6). The shortcomings oftreatment for such highly invasive and
metastatic disease have led to several investigations ofvarious molecular targets that
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directly affect invasion and metastasis in hopes of developing safe and effective
treatments.
Many studies suggest that Epithelial Mesenchymal Transition (EMT) may be an
important step leading to cancer metastasis (7-9). A notable mechanism by which E-
cadherin is downregulated in EMT is transcriptional repression by Snail (10, 11). The
transcription factor Snail, acts as a tumor promoter in cancer. Snail is associated with
decreased cell-cell adhesion and an increase in cell migration (12). Induction of Snail
expression has been noted in many EMT processes that have been studied (11,13,14).
Also, increase in survival pathways such as mitogen-activated protein kinase (MAPK) is
associated with increased Snail (15). Snail is composed oftwo interacting domains (16,
17) (13); the C-terminal domain is responsible for the binding to DNA sequences with a
5' CAGGTG'3 core while the N terminal is required for transcriptional repression (17,
18). Overexpression of Snail is sufficient to induce EMT and is associated with highly
invasive tumors in both mice and humans(19).
In order for a tumor to colonize to a secondary site it must invade the extracellular
matrix (ECM) (5, 6). Several proteolytic enzymes and their associated proteins are
involved in this process of degradation. Among them, is the plasminogen activation
system (PA system) which leads to activation ofmatrix metalloproteases (MMPs) (20,
21). Its members include urokinase-type plasminogen activator (uPA), plasminogen
activator inhibitors (PAI), and the uPA receptor (uPAR) (20, 21). uPA, when bound to its
cellular membrane- bound receptor uPAR, efficiently converts plasminogen into the
broad spectrum serine protease plasmin; its action on plasminogen is controlled by the
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serine protease inhibitors PAI-1 and PAI-2 (13-15). uPA catalyzes the activation of
plasminogen into plasmin by cleaving the arginine-valine bond. In turn, plasmin
facilitates the release of several proteolytic enzymes, including gelatinase and fibronectin
(20-22).
It has been well established that uPA and uPAR, both members ofthe PA system,
play a role in cancer invasion and metastases (20-24). It has been published that plasma
levels ofuPA and uPAR are higher in men with CaP than in healthy controls, and
significantly declined after prostate removal (25). Under normal conditions, uPAR is
thought to have fairly limited tissue expression (26). Studies using mice and human
clinical samples have identified conditions in which uPAR expression is induced (26,27).
uPAR is induced during ECM remodeling, stress, injury and inflammation, and is highly
expressed during tissue reorganization, inflammation, and in virtually all human cancers
(20,22,26). Furthermore, it has been shown that uPAR is under an ERK dependent
mechanism and blocking uPAR's activity leads to inhibition ofmotility in hepatocellular
carcinoma (28). In human gastric cancer, studies show that epidermal growth factor
(EGF) stimulates uPAR expression via ERK pathway sequentially increasing cell
invasion (29).
Several studies have shown that Snail mediates invasion through MMP activation
(30-32), however there are very few studies that link Snail and uPA to cancer
progression. One study indicated that silencing uPA expression in MDA-MB-231 breast
cancer cells decreased expression ofvimentin and Snail, and induced changes in
morphology characteristic of epithelial cells (33). These results demonstrate that uPAR-
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initiated cell signaling may be targeted to reverse EMT in cancer (33). Another study
suggested that when Snail is blocked in invasive breast cancer cell-line MDA-MB-231
there is a decrease expression in PAI-1 and uPA transcripts and less migration (34).
Previously, we have stably overexpressed Snail in LNCaP and ARCaP CaP cell
lines, and shown that Snail led to EMT associated with decreased/relocalized E-cadherin,
increased vimentin and increased migration (12, 35-37). Our understanding ofthe
molecular mechanisms of Snail-mediated cell invasion remains limited to MMP
activation while other proteases are less studied. Therefore, we hypothesize that Snail
increases invasion via uPA/ uPAR signaling. To test this hypothesis, the following aims
were investigated;
1. To determine the association between snail and uPA-uPAR expression in CaP.
2. To determine whether Snail can activate uPA/uPAR in CaP.
3. To determine the signaling pathway by which Snail regulates uPA-uPAR in CaP.
CHAPTER 2
LITERATURE REVIEW
2.1 The Prostate gland
The prostate gland is an exocrine gland located in the pelvic cavity that
completely surrounds the urethra, in front ofthe rectum in human males (Figure 1A) (38-
42). The main function ofthe prostate is to secrete an alkaline solution, made up of
glucose, fructose, and enzymes, that constitutes more than half of semen (43). Although
the prostate is small, weighing on average 11 grams in adult males, it is well defined.
Two types of tissue, exocrine glandular tissue and fibromuscular tissue make up the
prostate. There is an abundance of exocrine glandular tissue that functions in the
secretion of semen components. The fibromuscular tissue forms the outermost layer of
the prostate and the tissue surrounding the urethra. Its main purpose is to contract and
expel the seminal fluid. Pathologically, the prostate is divided into the peripheral,
central, and transition zones (See Appendix Figure IB) (40,44,45). The peripheral zone
that surrounds the distal urethra is the largest segment. It is this zone where chronic
prostatis, prostatic intraepithelial neoplasia (PIN), and prostate cancers (CaPs) originate
(44) (46). The central zone surrounds the ejaculatory ducts. Cancers originating in the
central zone are very rare but are more aggressive due to its ability to escape from the
gland through the ejaculatory ducts and seminal vesicles (47). The transition zone that
surrounds the proximal urethra is the smallest segment. Due to its ability to continue to
grow throughout life, it is the site of origin for benign prostatic hyperplasia (BPH) (44,
46). Histologically, the prostate is comprised oftwo cell types, stromal and epithelial (46,
5
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48). The epithelial cells make up the exocrine glandular tissue and contain basal, luminal
secretory, and neuroendocrine cells. The stroma contains fibroblast and smooth muscle
cells and make up the fibromuscular tissue.
The human prostate is observed by week 12 of gestation and continues
development until birth. During puberty, when hormone levels such as androgens rise in
males, prostate growth is renewed until early adulthood (49-51). Androgens are steroids
that contribute to male secondary characteristics. Two types of androgens that are
involved in prostate development are testosterone and dihydrotestosterone (DHT)(52).
Both androgens bind to the androgen receptor (AR) in the cytoplasm which induces a
receptor dimerization that facilitates the ability ofAR to bind to a specific response
element and recruit co-regulators that will aid in expression of specific genes that plays a
role in growth ofthe prostate.(53, 54).
2.2 Prostate Cancer
Prostate cancer (CaP) is the most commonly diagnosed malignancy in the United
States, with most cases occurring in men over the age of 55 (1). In 2013, about 238,590
new cases of CaP will be diagnosed and about 29,720 men will die of CaP in the United
States alone (1). The incidence and mortality rates ofCaP in African American men as
compared to Caucasian males are very alarming. This year alone, African American men
will account for 37% ofthe newly diagnosed incidence and have a mortality rate 2.4
times higher than Caucasian men (55-57). Unfortunately, according to the American
Cancer Society there is no single cause for these inequalities but may be due to the
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following: genetic variations, diets, exposure to environmental factors, and
socioeconomic disparities (55-57).
Prostate cancer is slow growing asymptomatic disease that tends to be diagonosed in
men over the age of 60. Currently, this is no cure ofprostate cancer so early diagnosis is
the best way to fight it. As early as age 40, men should begin screening for prostate
cancer. Prostate specific antigen (PSA) and digital rectal exams (DRE) are two common
test used in prostate cancer screening. Used as an early detection method, the PSA test
measures the blood level of a protein that is produced by the prostate (58-60). If the PSA
level is elevated then it is likely that there is a problem with the prostate (58). DRE is a
method by which a gloved, lubricated finger is inserted into the rectum to feel the
prostate. This allows the examiner to feel for any lumps or abnormalities. To confirm
prostate cancer a biopsy is performed in which prostate tissue is removed and examined
microscopically. Following diagnosis the patient with early stage of CaP that is localized
in the prostate has limited treatment options including, minimally invasive surgery,
chemotherapy, radiation and prostate removal. About 30% oftreated patients suffer
relapse and progress to hormone refractory prostate cancer (HRPC), which no longer
responds to androgen ablation whereas early CaP growth is androgen dependent. At that
stage, there is no curative therapy available for metastatic CaP (3,4).
2.3 Metastasis
Metastasis is a complex process by which tumor cells dissociate from the primary
tumor and migrate to a secondary site where they recolonize. It consists of multiple steps
that are interconnected (5, 6). The initial event ofthe metastatic cascade is tumor
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invasion. During this step, the tumor cells produce and secrete many proteolytic enzymes,
such as matrix metalloproteinases (MMPs). This allows the tumor cells to disrupt the
basement membrane by cleaving extracellular matrix (ECM) components such as
fibronectin, vitronectin and collagen. Consequently, cell surface receptors called
integrins bind to these ECM components signaling the tumor cells to remodel actin
cytoskeleton and become migratory. This marks the beginning ofthe second step of
metastasis, which is migration. Following migration through the ECM, tumor cells enter
blood or lymphatic vessels in a process known as intravsation. Once in the blood vessels
the tumor cells gain direct access to nutrients but lose access to the survival signals they
were receiving in their former tumor environment. One way by which metastatic tumors
overcome these pitfalls is by acquiring resistance to cell death by overexpressing anti-
apoptotic proteins and upregulating cell survival pathways such as AKT and MAPK.
During the final steps of the metastatic cascade, the tumor cells then decide to extravaste
through the endothelial cell layer ofthe blood vessels and surrounding basement
membrane (BM) to the target organ tissue where they form a secondary tumor at the
target organ site (14, 61, 62). Although cancer has been known to metastasize to the
brain, lungs, and liver, the secondary organ of choice for prostate cancer is to the bones
(63, 64). One popular hypothesis for different cancers spreading to specific distant sites
came from Stephen Paget who proposed a 'seed and soil' hypothesis (65). According to
Paget the disseminated tumor cells (seed) colonize to specific organs whose
microenvironment (soil) is compatible for their growth and proliferation (65).
Fortunately, the entire metastatic cascade is highly inefficient due to the inability ofmore
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than 99.95% ofthe migrating tumor cells to complete any ofthe above steps (66).
However, metastasis is the major cause of death in epithelial malignancies (67). The
shortcomings oftreatment for such highly invasive and metastatic disease have led to
several investigations ofvarious molecular targets that directly affect invasion and
metastasis in hopes of developing safe and effective treatments.
2.4 Epithelial Mesenchymal Transition (EMT)
Many studies suggest that Epithelial Mesenchymal Transition (EMT) may be an
important step leading to cancer metastasis (7-9). EMT is essential in normal
development and may be characterized by a shift in epithelial phenotype to a
mesenchymal phenotype. The main difference between the two phenotypes is that
epithelial cells are attached to the ECM rendering them immobile whereas mesenchymal
cells are fibroblastly shaped and are mobile. In the literature, EMT has been characterized
as 3 different types (68, 69). Type 1 EMT occurs during embryogenesis and organ
development giving rise to primary mesenchymal cells. Type 2 EMT is associated with
inflammation and plays a role in wound healing and tissue regeneration and ceases once
inflammation is attenuated. Type 3 EMT is not part ofnormal biological development but
is rather a result of disorderly conduct of tumor cells. This type ofEMT is a precursor to
metastasis (68). It enables the tumor epithelial cells to acquire the morphology to
infiltrate surrounding tissue with ease. There are many biomarkers used to detect all three
types ofEMT with a common attenuated marker being epithelial cadherin (E-cadherin)
(CDH1), a cell-cell adhesion protein (Figure 2) (70). During the EMT, E-cadherin
expression is downregulated leading to a decrease in cell-cell adhesion. A notable
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mechanism by which E-cadherin is downregulated in EMT is transcriptional repression
by Snail (10,11).
2.5 Snail Super Family
One transcription factor that can induce EMT is Snaill (62). Over 20 years ago,
Snail was initially described in Drosophila melanogaster, where it was shown to play an
important role in mesoderm formation(71, 72). The Snail Superfamily consist of three
isoforms: Snaill (more commonly known as Snail), Snail2 (more commonly known as
Slug) and Snail3 (more commonly known as Smuc). These transcription factors share
common structural features including a conserved DNA-binding carboxy-terminal
domain with characteristic C2h2-type zinc finger repeats. They act as transcriptional
repressors by binding to CAGGTG E-box sequences. Snail2 is more broadly expressed
than Snaill, and its expression appears in some cases unrelated to EMT. Additionally,
Snail3 is less investigated due to it being more recently characterized. When compared,
Snaill binds to these sequences with a higher affinity than Snail2 and is a more potent
inhibitor of CDH1 and other target genes(7, 62, 73)(148).
2.5.1 Snail
Snail is composed oftwo well defined domains that interact with each other (7).
The C-terminal domain is responsible for binding to the DNA and presents specificity for
sequences with a 5' CAGGTG'3 core. The N-terminal is required for transcriptional
repression and can recruit histone deacetylase family members. Snail repressive activity
can also be modulated by phosphorylation of a proline-serine- rich sequence situated in
the regulatory domain. Two phosphorylation motifs have been allocated in this
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subdomain, one involved in Snail export from the nucleus, and the other in its
ubiquitinylation and degradation. Glycogen synthase kinase-3P (GSK-3P) has been
reported to be responsible for the modification ofboth motifs (7, 62, 73)(148). The
expression of LIV1, a zinc transporter, regulates the import of Snail to the nucleus.
Moreover, the C-terminus of Snail protein can be phosphorylated by PAK-1 at S246; in
this case this modification maintains the protein in the nucleus enhancing its transcription
activity (7, 62, 73)(147). CRM1, an exportin, is involved in exporting phosphorylated
Snail from the nucleus back to the cytoplasm (16).
2.5.2 The Role of Snail in Prostate Cancer
Induction of Snail expression has been noted in many EMT processes that have
been studied (147-148). Signaling pathways such as transforming growth factor P (TGFP)
and epidermal growth factor (EGF) have been shown to activate Snail and induce EMT
(Figure 3) (15). One ofthe first promoters shown to be directly repressed by human Snail
was E-cadherin(74). Snail's SNAG domain binds to the E-boxes in the E-cadherin
promoter repressing transcription and by recruiting histone deacetylases (HDAC 1 and 2),
which increase binding between DNA and chromatin therefore condensing DNA and
preventing transcription. Additionally Snail represses E-cadherin by overexpressing other
E-cadherin repressors such as Zeb-1 and Zeb-2. In conjunction with repressing E-
cadherin, Snail also plays a role in the repression of other tight junction proteins such as
claudin and occludin (Figure 4). Loss of E-cadherin and other tight junction proteins
marks a crucial step in EMT therefore increasing invasion of epithelial carcinomas. In
support ofthis hypothesis, Snail expression is elevated at the leading edge of invasive of
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squamous cell carcinoma (75). Snail has been shown to be expressed in many different
tumors that display invasive characteristics such as, breast, ovarian, and prostate cancer
(19, 76-79). These tumors cells that have increased Snail expression also have poor
clinical outcome. Particularly in prostate cancer, Snail is correlated with high metetastatic
tumors (19, 79). Studies done in clinical specimens, in vivo, and in vitro further provide
evidence that Snail expression increases with prostate cancer progression (79-81). In a
response to Snail repressive activity, proteases are upregulated allowing tumor cells to
acquire invasive properties.
2.6 Proteases
An important factor in determining whether or not tumor cells will metastasize is
destruction ofthe ECM. In order to accomplish this task tumor cells secrete proteases.
Proteases are group ofprotein-degrading enzymes that catalyzes the hydrolysis ofpeptide
bonds (82). Although they make up 2% of all proteins they are involved in many
physiological processes such as blood coagulation, digestion, ovulation and fertilization
(83). Proteases are modulated by protease inhibitors. Under normal biological conditions,
extracellular proteases and inhibitors help maintain tissue homeostasis (84). However,
poor regulation ofproteases and inhibitors can lead to disease such as Alzheimer's
disease, muscle degradation, rheumatoid arthritis, tissue inflammation and cancer
metastasis(85-87).
Proteases are well defined;They are classified based on their cleavage location
and their catalytic mechanism. Exopeptidases cleave at the amino or carboxy terminus
whereas endopeptidases cleave in the inner region ofpolypeptide chains (88).
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Furthermore,proteases are divided into five classes based on catalytic mechanism
incuding; aspartic, cysteine, metalloproteinases, serine, and threonine (89). All five
classes ofproteases have been shown to play a role is disease (85-87). Specifically,
serine and metalloproteinase proteases have been shown to play a major role in tumor
metastasis (90). The serine proteases (e.g. uPA) lead to the degradation of collagen,
elastin, glycoproteins and proteoglycans. The MMPs are capable of degrading collagen,
glycoprotein, and proteoglycan components. TGF0 activation of Snail leads to the
activation ofMMPs.
2.6.1 Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) are a family of structurally related and highly
conserved zinc-dependent endopeptidases collectively capable of degrading most
components ofthe basement membrane and ECM (91). There are over 20 human MMP
members divided in two groups based on their cellular localization (secreted versus
membrane-bound), or in five main groups according to their structure and substrate
specificity: collagenases, gelatinases, membrane type, stromelysins and matrilysins .
MMPs are synthesized as inactive proenzymes (pro-MMPs), and they share several
conserved structural domains. Plasma associated MMPs are inhibited by liver secreted
a2-macroglobulin, while extracellular MMPs are regulated by their endogenous inhibitors
named Tissue Inhibitor ofMetalloproteinases (TIMPs) (6,21,30, 31, 91-95).
Normally the MMPs are expressed only when and where needed for tissue
remodeling that accompanies various processes such as during embryonic development,
wound healing, uterine and mammary involution, cartilage-to-bone transition during
14
ossification, and trophoblast invasion into the endometrial stoma during placenta
development (6, 21, 30, 31, 91-95). However, aberrant expression of various MMPs has
been correlated with pathological conditions, such as periodontitis, rheumatoid arthritis,
and tumor cell invasion and metastasis (6, 30, 31, 95). Expression of various MMPs has
been found to be up-regulated in virtually every type ofhuman cancer and correlates with
advanced stage, invasive and metastatic properties and, in general, poor prognosis (6, 30,
95).
2.7 The Urokinase Plasminogen Activator System
The Urokinase Plasminogen Activator System is primarily associated with the
degradation and regeneration of the basement membrane and the extracellular matrix that
leads to metastasis (13,15). It is a serine protease family comprising ofurokinase-type
plasminogen activator (uPA), plasminogen activator inhibitors (PAI), and the uPA
receptor (uPAR). uPA, when bound to its cellular receptor uPAR efficiently converts
plasminogen into the broad spectrum serine protease plasmin; its action on plasminogen
is controlled by the serine protease inhibitors PAI-1 and PAI-2(23, 33, 96). Plasmin
disintegrates various components ofthe connective tissue, and in malignancy, the tumor
stroma surrounding the tumor cell nests. uPA catalyzes the activation ofplasminogen into
plasmin by cleaving the arginine-valine bond, m turn, plasmin facilitates the release of
several proteolytic enzymes, including gelatinase and fibronectin (Figure 5) (1,20,22,
23, 97-99). Interaction ofPAI-1 with the uPA/uPAR-complex induces internalization of
the ternary complex uPAR/uPA/PAI-1 via help of transmembrane receptors ofthe LDL-
receptor family, which subsequently results in intracellular degradation ofuPA and PAI-
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1, while uPAR is recycled to the cell surface. By this, the proteolytic activity is efficiently
reorganized on the cell surface enabling pericellular proteolysis PAI-2 also forms a
ternary cell surface associated complex with uPA and uPAR (uPAR/uPA/PAI-2), but this
is not internalized; in contrast, PAI-2 is degraded once bound to uPAR/uPA (1,13, 20,
22-24, 27, 96-98, 100).
PAI1 is a chain glycoprotein that is expressed in three forms: the latent inactive
form, the form complexed with tPA or uPA, and the free active form, the most
represented form.(101) Studies reveal two unique roles of PAI1 in cancer metastasis.
First, PAI1 binds to receptor bound uPA and deactivates uPA then the PAI1- uPA-uPAR
complex is internalized where uPAR is recycled and shipped back to the cell membrane.
Secondly, PAI1 can bind to ECM proteins such as vitronectin, fibronectin and type-1
collagen, disrupting integrin binding which leads to detachment of cells from the ECM
(101,102). Many studies suggest that PAI1 plays a role in mediating breast carcinoma
progession and may be used as a biomarker (103-105). Additionally Snail inhibition has
been shown to decrease PAI1 expression in breast cancer cells(34). A study done by R.
Czekay et.al suggests that PAI1 detaches cells from ECM by inactivating intergrins
(102). It is also suggested that PAI1 regulates cell adhesion through a uPAR dependent
mechanism (106).
2.7.1 uPA
The human uPA gene is located on chromosome 10 and is a 411-residue protein,
consisting ofthree domains: the serine protease domain, the kringle domain, and the
growth factor domain. The C-terminal (amino acids 144-411) is the heavy chain that has
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a carboxy- terminal region with a serine protease domain (107). The kringle domain
(amino acids 46-143) contains the sequences that interacts with PAI-1 (107). The N-
terminal domain (amino acids 9-45) is the light chain that is referred to as the amino
terminal fragment and is responsible for uPAR binding (107, 108). uPA is synthesized as
a zymogen form (pro-uPA), and is activated by proteolytic cleavage between LI58 and
1159 uPA (1,13,20,22-24, 33, 96-98).The two resulting chains are kept together by a
disulfide bond.
uPA was originally discovered in human urine at very high concentrations ,
although it is found in blood plasma, semen and other bodily fluids (109,110). Human
uPA is produced by many cell types within the body mainly epithelial cells including
renal epithelil cells ofthe proximal and distal kidney tubules and glomerular visceral
epithelial cells. During angiogenesis, uPA is also expressed by endothelial cells. The
expression ofuPA is upregulated in a number of cancers including breast, cervical, lung,
brain, oral, colon, bone and prostate cancers (103, 111, 112). During prostate
development proteases such as uPA may be important in remodeling ofthe extracellular
matrix. In the prostate and semen, uPA is believed to play a role in sperm motility and
maturation (113). Many studies have shown that uPA is the predominant plasminogen
activator in hyperplastic and malignant prostate tissue (114-1^). Elevated uPA in the
serum ofpatients with CaP is associated with the development ofCaP metastasis (117,
118). Specifically, elevated uPA is correlated with increased activation ofMMP-2 and
MMP-9 (119-121). Growth factors such as TGF-0 have been shown to activate the
transcription ofuPA and lead to elevated uPA activity, although the exact mechanism is
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unknown (122). Evidence shows that latent form TGF-0 undergoes proteolytic
activation by uPA in CaP resulting in the overexpression ofuPA, increased activation of
MMP-9 and increased tumor cell invasion ofmatrigel (123,124).
2.7.2 uPAR
uPA binds to the membrane bound protein uPAR, which localizes ECM and BM
degradation and promotes cell invasion (125). uPAR is associated with the external
surface ofthe plasma membrane by a glycosyl phosphatidylinositol (GPI) anchor. uPAR
is also secrected from the cells as soluble form (suPAR). uPAR is a 55 kDa glycoprotein
that consists ofthree different domains; the uPA binding dmainl (Dl), the connecting
domain 2 (D2) and the cell anchoring domain (D3) (99,103,126,127). Upon forming the
uPAR-uPA-PAI complex, the receptor is immediately internalized through clathrin-
coated pits in cell membranes. The uPA is degraded in the lysosomes and uPAR is
recycled to the cell surface to rebind with another uPA molecule (107).
Under normal conditions, uPAR is thought to have fairly limited tissue expression
(22). Studies using mice and human clinical samples have identified conditions in which
uPAR expression is induced (22, 33). uPAR is induced during ECM remodeling, stress,
injury and inflammation, uPAR is highly expressed during tissue reorganization,
inflammation, and in virtually all human cancers (22, 33, 98,128). In addition to uPA,
uPAR also has other high affinity ligands such as vitronectin and integrins. Their
interaction with uPAR facilitates the non-proteolytic functions including adhesion and
migration thereby promoting cancer progression (99,129-132). This paper will focus on
the proteolytic function ofuPAR with its ligand uPA. Additionally, although GPI-uPAR
18
and suPAR both have high affinity for uPA, GPI- uPAR is more susceptible to uPA-
cleavage than suPAR(133,134). Therefore, GPI-uPAR will be the focus of our studies.
2.8 Cell signaling: The Mitogen-Activated Protein Kinase (MAPK) Pathways
Cells must be able to adapt to biological changes as living organism. Fortunately
healthy cells are able to communicate with one another and are able to properly
determine when to proliferate, undergo senescence, or apoptosis. Growth factors,
cytokines, and hormones which are secreted into the ECM binds to receptors and sends
signals that regulate gene expressions and cell growth. The process by which a cell
converts this signal into a biological function is known as signal transduction.
Multicellular organisms require numerous signaling pathways in order to function as a
whole organism. Some extracellular receptors include integrins, G- protein coupled
receptors (GPCRs), receptor tyrosine kinases (RTKs) and toll like receptors. These
receptors are transmembrane proteins that have a high affinity for ligand binding.
Mutations or overexpression in either the receptor or the ligand can cause a defect in
signal transduction leading to disease state. Cancer is the result ofuncontrolled cell
division therefore, mutations and overexpressions plays an essential role in its
progression.
One signaling pathway that has been implicated in the progression of cancer is
the mitogen activated protein kinase (MAPK) pathway (135,136). MAP kinases are a
family of evolutionarily conserved protein kinases that was first characterized in yeast
(137-139). Four major MAPK pathways have been elucidated, including extracellular
signal- regulated kinase 1/2 (ERK 1/2), c-Jun amino terminal kinase (JNK), p38 MAPK,
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and ERK5 (140-144). These pathways play an essential role in mediating cellular
proliferation and differentiation. Activation ofthe MAPK pathways is initiated by
extracellular stimulus (i.e. growth factor, cytokine or mitogen) followed by a "three
tiered" phosphorylation cascade (139). MAP kinase kinase kinase (MAP3K) activates
MAP kinase kinase (MAP2K) which in turn activates MAPK leading to a biological
response (Figure 6).
In the literature, ERKl/2 is considered the classical MAPK pathway and is
activated by many extracellular stimuli. Mitogens such as EGF,FGF, NGF, and PDGF
bind to receptor tyrosine kinases (RTKS) and activate the ERKl/2 pathway(145-147).
ERKl/2 model is regulated in a Ras dependent manner and contains MAPKKKs (A-Raf,
B-Raf, Raf-1, Mos and TPL-2), MAPKKs (MEKl and MEK2), and the MAPKs (ERK1
and ERK2) (145-147). Whereas,the JNK and p38 MAPK pathways are activated in a
response to stress (138). Inflammatory cytokines such as tumor necrosis factor alpha
(TNFa) and interleukin-1 (EL-1) and environmental stress including UV radiation and
heat shock activated both INK and p38 MAPK pathways (138). The final pathway ERK5
is activated by both mitogens and stress. ERK5 activation is very similar to ERKl/2
although it retains a unique c-terminal domain that acts as a transcriptional activator
(144). Additionally, ERK5 can act as a transcription factor (144).
At the MAPK level, the ERKl/2 is composed oftwo main proteins which are
ERK1 and ERK2. They are both activated by dual phosphorylation oftheir Thr-X-Tyr
motifby MEKl and MEK2. Upon activation by phosphorylation the ERKs translocate to
the nucleus by dimerizing or direct interaction with nuclear pore proteins since ERKl/2
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lacks a nuclear localization sequence (148-150). Once in nucleus they phosphorylate Pro-
X-Ser/Thr-X-Pro consensus sites of transcription factors such as p53, STAT, and cFos .
Inactivation ofERK1/2 activity is mediated by phosphatases which remove a phosphate
on Thr and Ty residues. Although both Erkl and Erk 2 share similar structure, substrates
and localization patterns differences in functions do occur. Mice studies show that unlike
ERK1 deficiency, ERK 2- deficient mice are embryonic letha 1 (144).
Increased activation ofthe ERK1/2 pathway has been shown to play a major role
in cancer progression. Two inhibitors, PD98059 and U0126, have been synthesized in
order to study the role ofERK in cancer (151-153). Both inhibitors target
unphosphorylated MEKl and MEK2 thereby leading to inhibition ofERK1/2 (151-153).
U0126 inhibits both MEKl and MEK2 whereas PD98059 inhibits MEKl more potently
than MEK2 (151-153). Overexpression oftranscription factors such as Snail has been
shown to increase ERK1/2 phosphorylation in cancer (12,15). Additionally Snail has
been shown to signal through ERK1/2 in prostate cancer (12). Snail has been shown to
negatively regulate cell adhesion to the ECM via ERK1/2 thereby promoting cell
migration, although the exact mechanism by which snail signals through ERK1/2 is not
known .Also, proteases such as uPA lead to increased activation ofthe MAPK pathway
(154,155). During the non-proteolytic pathway, uPAR-uPA forms a complex with
vitronectin and integrins resulting in an increase MAPK signaling.
CHAPTER 3
MATERIALS AND METHODS
3.1 Reagents and antibodies
RPMI medium and penicillin/streptomycin were purchased from VWR Int., West
Chester, PA. The protease inhibitor cocktail was from Roche Molecular Biochemicals,
Indianapolis, IN. G418 and anti-human actin antibodies were from Sigma-Aldrich, Inc.,
St Louis, MO. Rabbit polyclonal anti-human Snail antibody and rabbit anti- phospho-
ERK1/2 (p-ERK) were from Cell Signaling Technology, Inc., Danvers, MA. Rabbit
polyclonal anti-uPA, anti-uPAR, and anti- total- ERKl/2 (t-ERK) were purchased from
Santa Cruz Biotech (Santa Cruz, CA). HRP-conjugated sheep anti-mouse, sheep anti-
rabbit and the ECL Prime or ECL Plus chemiluminescent reagents were obtained from
GE Healthcare Life Sciences, Buckinghamshire, UK. Fetal bovine serum (FBS) and
Charcoal/dextran treated FBS (DCC-FBS) were from Hyclone, South Logan, UT.
Control and Snail siRNA constructs were from Dhannacon, Lafayette, Co. UO126 was
purchased from (Sigma). uPA activity assay kit was from Chemicon (Billerica, MA).
Matrigel was purchased from BD Biosciences Bedford, MA.
3.2 Cell Culture
Human prostate cancer cell line ARCaP stably transfected with constitutively
active Snail cDNA (ARCaP Snail representing an aggressive cell line) or an empty vector
Neo (ARCaP Neo representing the lesser aggressive cell line) as well as LNCaP cells
overexpressing Snail have been previously described to represent an EMT model and
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were utilized in these experiments(12, 35-37). 22Rvl cells overexpressing Snail utilized
in these experiments were previously generated(35) . LNCaP human prostate cancer cell
line was obtained from ATCC, Manassas, VA and maintained in RPMI164 (Cellgro),
supplemented with 10% fetal bovine serum (FBS), 1% non-essential amino acids, and 1%
antibiotics at 37°C in 5% CO2. The Snail-transfected cells were maintained in RPMI
1640 supplemented with 10% FBS, 1% non-essential amino acids, and 1% antibiotics
plus 400 ug/ml G418. All cells were maintained at 70% to 80% confluence.
3.3 Western Blot Analysis
Cells were cultured to 85-90% confluency; subsequently cells were washed with
PBS and harvested in modified RIPA buffer (50 mM Tris, pH 8.0,150 mM NaCl, 0.02%
NaN3, 0.1% SDS, 1% NP-40,0.5% sodium deoxycholate) containing 1.5X protease
inhibitor cocktail, 1 mM phenylmethylsufonyl fluoride, and 1 mM sodium orthovanadate.
Protein concentrations were calculated using the BCA protein assay from Pierce
(Rockford, IL). Equal concentrations ofwhole cell protein were separated on a 10%
SDS-PAGE gel and transferred to a nitrocellulose membrane. Non-specific antibody
binding sites were blocked using 3% or 5% nonfat dry milk and Tween 20/TBS (TBS-T)
and washed with TBS-T. Membranes were incubated with primary antibodies in 3%
BSA-TBST (p-ERK, Snail), or 5% nonfat dry milk-TBST (uPA, uPAR, ERK 1/2, 0-
actin) overnight at 4°C. Membranes were washed in TBS-T and incubated with
secondary horseradish peroxidase-conjugated secondary antibody anti-rabbit (Snail, uPA,
uPAR, p-ERK) or anti-mouse secondary antibody (actin), then washed in TBS-T.
hnmunoblots were detected using ECL Prime or ECL Plus chemiluminescent reagent.
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3.4 uPA Activity Assay
uPA activity was measured in conditioned medium from the human prostate
cancer cell sublines LNCaP Neo/Snail, ARCaP Neo/ Snail, and 22Rvl Neo/Snail using
the uPA activity assay kit according to manufacturer's instructions. A chromogenic
substrate, a tripeptide with the attached chromophore para-nitroaniline (pNA) group, is
cleaved by active uPA to produce a color product, which is detected on a plate reader at
405 nm. Active uPA was calculated relative to standards provided with the kit.
3.5 Short Interfering RNA (siRNA) Transfection
Transient transfection ofuPAR siRNA was performed on ARCaP Snail cells
using Dharmafect 1 reagent. Cells (lxlO6/well) were seeded in a 6-well plate and
transfected with 200 nm uPAR-siRNA or control-siRNA in serum free media at 37°C
with 5% CO2 for 5 hours, followed by replacement of transfection media with RPMI
supplemented with 5% DCC-FBS. 72 hrs later, transfected cells were washed with PBS
in modified RIPA buffer (50 mM Tris, pH 8.0,150 mM NaCl, 0.02% NaN3, 0.1% SDS,
1% NP-40, 0.5% sodium deoxycholate) containing 1.5X protease inhibitor cocktail, 1
mM phenylmethylsufonyl fluoride, and 1 mM sodium orthovanadate. Protein
concentrations were calculated using the BCA protein assay from Pierce (Rockford, IL).
Cell lysates were used for Western blot analysis of Snail, uPA, uPAR, and P-actin;
conditioned media was collected for uPA activity assay. Transfected cells were also
utilized for a subsequent invasion assay.
3.6 Invasion Assay
The invasive properties of the cell lines were measured using the BD BioCoat
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Matrigel Invasion guidelines. Briefly, inserts were coated with 50 ul 1:4 matrigel and
allowed to solidify at 37°C for 1 hour. Cells were seeded in quadruplicate at 5xlO4 (for
ARCaP and 22Rvl) and lOxlO4 (for LNCaP) in 0.1% FBS, while the lower chamber
contained 10% FBS. Cells were treated accordingly and allowed to invade through the
porous membrane coated with matrigel 37°C for 24-72 hours. Inserts were fixed, stained
and pictures were taken in 2 different fields/insert. Cell counts were done for
determination of relative invasion or the stain solubilized with Sorenson solution and
optical density (OD) measured at 590 nm.
3.7 ERK Inhibitor Assay Treatments
The human prostate cancer cell subline ARCaP Snail (lxlO6) was cultured
overnight. The following day, cells were treated with 20 DM ERKl/2 inhibitor (U0126)
at the following time points (0 mins, 30 mins, 2 hours, 6, hours, 24 hours, and 72 hours).
The condition media was collected and whole cell lysates were collected as previously
described.
3.8 SuperArray Analysis
Total RNA was isolated from ARCaP Neo or ARCaP Snail cells using the Qiagen
kit as per manufacturer's instructions, and 1 ug reverse transcribed with oligo-dT using
MMLV-reverse transcriptase (Invitrogen), to generate cDNA. The labeled cDNA was
incubated with GEArray-Q Series cancer pathway membranes (SuperArray,
SABioscience) at 60°C overnight. The membrane used in the present study contained 96
genes that were closely related to cancer pathways, in addition to housekeeping control
genes (GAPDH etc.). After being washed, the membrane was incubated with
25
streptavidin-alkaline phosphatase and was finally exposed to CDP-Star chemiluminescent
substrate (SuperArray). Signal detection was performed using a high Performance
chemiluminescence film (Amersham Biosciences). Analysis of results was performed by
GEArray Expression Analysis Suite software fhttp://geasuite.superarray.com').
3.9 Statistics and Quantifications
All data were presented as the mean ± SE of at least three independent
experiments. The data was analyzed for two-way ANOVA or Student t-test. All statistical




4.1 Overexpression of Snail leads to an increase in cell invasion
Previously, we have shown that Snail overexpression increases cell invasion in
22Rvl cells (35). To confirm these results and examine the effect of Snail overexpression
on LNCaP and ARCaP invasion through the ECM, we performed an invasion assay
where matrigel mimicked the ECM. As expected, Snail-transfected cells displayed
significantly more cell invasion as compared to the Neo control-transfected cells in all
three cell lines tested (Figure 7). Therefore, Snail is associated with increased cell
invasion.
4.2 Overexpression of Snail leads to an upregulation of uPA and uPAR
In order to examine the molecular mechanism by which Snail may increase cell
invasion, we next performed a superarray analysis on ARCaP Neo and ARCaP Snail
prostate cancer cells to identify genes downstream of Snail, which may be responsible for
the cells' increase in invasion. Interestingly, a protein associated with cell invasion, uPA
and its receptor uPAR was upregulated (Figure 8.a). Next we evaluated the protein
expression ofuPAR and its ligand uPA in Snail overexpressing LNCaP , 22Rvl and
ARCaP cells. In all three CaP lines, Snail transfection increased uPA and uPAR protein
expression (Figure 8.b). Additionally, measurement of secreted uPA activity in
conditioned media showed that LNCaP, 22Rvl and ARCaP cell lines overexpressing
Snail displayed higher uPA activity as compared to the Neo control (Figure 8.c). The
results also suggested that the androgen-independent ARCaP cells had higher active uPA
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as compared to the androgen-dependent LNCaP and 22Rvl cells. Therefore, Snail is
associated with increased uPa/uPAR protein levels and increased uPA activity.
4.3 uPAR knockdown in Snail-overexpressing ARCaP cells leads to decreased cell
invasion
To evaluate the contribution ofuPA/uPAR in the increased invasion that was
observed in the Snail overexpressed cells, we transiently knocked down uPAR in ARCaP
Snail cells, western blot analysis confirmed the knockdown ofuPAR (Figure. 9.a).
Interestingly, uPAR knockdown was accompanied by a decrease in uPA protein
expression, while Snail expression was not affected by this knockdown (Figure 9.a).
Functionally, there was a significant decrease in invasion following uPAR knockdown
(Figure 9.b). Thus uPAR contributes to Snail-mediated cell invasion.
4.4 Inhibition of MAPK activity downregulates uPA activity and decreases cell
invasion
We have previously shown there is an increase ofphosphorylated MAPK (p-
ERK) in prostate cancer cells overexpressing Snail (12, 36). Therefore we investigated
whether Snail regulation ofuPA activity could be mediated by MAPK signaling. We
confirmed that Snail overexpression increases ERK activity in both LNCaP and ARCaP
cell lines (Figure lO.a). Next, we treated Snail-transfected ARCaP cells with 20 uM
UO126 MEK inhibitor for 30 mins, 2 hours, 6 hours, 24 hours and 72 hours. Decreased
ERK activity was observed by 30 mins and persisted until 72 hours as shown by western
blot analysis (Figure lO.b). We also found that inhibiting MAPK activity significantly
decreased uPA activity within 30 mins (Figure lO.c). Finally, ARCaP Snail cells treated
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with U1O26 for 24 hours showed decreased invasive potential as compared to the
ARCaP Neo control (Figure lO.d).
CHAPTERS
DISCUSSION
Studies suggest that epithelial mesenchymal transition (EMT) is an important step
leading to cancer metastasis (7-9). One mechanism by which E-cadherin is
downregulated in EMT is transcriptional repression by Snail (10, 11). In this study we
have shown that an overexpression of Snail increases cell invasion in both androgen-
dependent LNCaP and 22RV1 and androgen-independent ARCaP prostate cancer cell
lines. In Snail-transfected ARCaP we evaluated via superarray analysis some genes that
were upregulated and downregulated based on their function. The results ofthe
superarray demonstrated that an overexpression of Snail leads to upregulation of genes
involved with invasion and metastasis such as uPA and uPAR. It was interesting that
both uPA and uPAR were upregulated in Snail-transfected prostate cancer cells because
in previous studies done in PC3 and DU145, RNA interference of uPA and uPAR
resulted in uPA and uPAR's mRNA and protein expression to be completely inhibited,
and there was a decline in metastasis (156). Although they did not determine the
signaling cascade as to how the expression ofuPA and uPAR was downregulated, our
supperarray analysis and uPAR siRNA studies done in Snail-transfected cells suggest that
it may be through Snail. To confirm our superarray studies we showed that uPA and
uPAR protein expression was increased in Snail-overexpressing cells. Additionally, Snail
overexpression led to increased uPA activity. Although there was a general increase in
uPA activity in the Snail-transfected cells, there was more uPA activity in the androgen-
independent ARCaP cells as compared to androgen-dependent LNCaP and 22Rvl cells.
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To determine the role the uPA/uPAR system has on the increase in invasion we observed
in Snail-transfected cells, we transiently knocked down uPAR. The most known
activator ofuPA is uPAR therefore by knocking down uPAR we are inhibiting the
function ofboth uPA and uPAR (20). We found that uPAR knockdown in ARCaP Snail
cells led to a significant decrease in cell invasion. It is important to mention Snail
expression was not affected by the knockdown ofuPAR suggesting that uPAR is acting
downstream of Snail to increase cell invasion; therefore, for the first time we show that
Snail relies on uPAR to increase invasion. It can be suggested that uPA/uPAR signaling
alone does not play an important role in Snail-mediated invasion in ARCaP cells since
uPAR knockdown did not completely eliminate invasion. Previously, we have shown that
ERK activity is increased in Snail-transfected ARCaP cells (12, 36). In this study, in
order to determine if Snail mediates invasion through MAPK pathway we treated Snail
transfected cells with MEK inhibitor UO126 at various time points. uPA activity and
invasion was significantly decreased in ARCaP Snail cells treated with UO126 in a time
dependent manner. This suggests that Snail may use the MAPK pathway to mediate cell
invasion through uPA/uPAR signaling in ARCaP cells. Supporting our results the
literature suggest that uPAR is under an ERK dependent mechanism and blocking
uPAR's activity leads to inhibition ofmotility in hepatocellular carcinoma (28).
Additionally, studies show that EGF stimulates uPAR expression via ERK pathway
sequentially increasing cell invasion in human gastric cancer (29). Although the activity
ofuPA was decreased upon MAPK inhibition, it was not completely eliminated possibly
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because its activity could be mediated by additional pathways such as AKT. In breast
cancer, studies have shown that upon uPA binding to uPAR, AKT is activated (73,157).
Overall, our results show for the first time, a link between Snail, MAPK and
uPA/uPAR in prostate cancer. Our studies suggest that Snail overexpression increases




Snail plays an important role in mesoderm formation during
embryogenesis. However, during cancer progression it is overexpressed and plays
a role in EMT and metastases. In the current study we have shown that Snail
overexpression leads to increased cell invasion in prostate cancer cells, which
could be antagonized by uPAR silencing. Snail also increased levels ofuPA and
uPAR protein as well as uPA and ERK activities. Furthermore, the inhibition of
MAPK activity decreased uPA activity and cell invasion. Our studies show for the
first time a link between Snail, MAPK and uPA/uPAR in prostate cancer. In
conclusion we show that Snail regulates cell invasion via uPA-uPAR activites,
possibly through the MAPK pathway (See Appendix Figure 11).
For future studies it would be interesting to determine the exact
mechanism by which Snail upregulates uPA and uPAR. One possible method is
through direct binding of Snail to either the uPA and uPAR promoter. Mapping
the pathway by which Snail, uPA, and uPAR is overexpressed in prostate cancer
may provide significant implications for treatment ofprostate cancer metastasis.
Although both Snail and uPA-uPAR have been studied in cancer, it may be
beneficial to focus cancer treatment on targeting both Snail and uPA-uPAR. in
order to prevent EMT and tumor cell invasion since tumors consist of cells at





Figure 1. The adult prostate and surrounding structures, (a) The base of the
prostate is located at the neck ofthe bladder. The urethra bisects the prostate.
Image taken from (46). (b) The three histologically distinct zones are shown: the
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Figure 2. The epithelial-mesenchymal transition. Epithelial-to-Mesenchymal
Transition (EMT) is a process in which epithelial cells lose their characteristics
and gain mesenchymal properties.. The EMT process is induced and regulated by
effectors such as growth ECM components. It is characterized by loss of epithelial
markers such as E-cadherin and cytokeratins and gain ofmesenchymal markers
such as N-cadherin and vimentin. Figure taken from (70).
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Figure 3. Numerous signaling pathways induce EMT and Snail transcription.
Many signaling pathways have been shown to induce epithelial to mesenchymal
transition (EMT). Additionally these pathways also activate Snail expression.
Also, Snail is regulated by subcellular localization by GSK3 and PAKl kinase
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Figure 4. Downstream effects of snail. The expression of Snail affects the
expression of proteins that plays a role in EMT, proliferation, cell survival, and
cell invasion. The red arrows next to the proteins represent a decrease in activity
or expression in response to Snail either directly or indirectly. In contrast, the
green arrows represent an increase in activity or expression in response to snail





Figure 5. uPA-uPAR binding. At the leading edge of migrating cells the
urokinase receptor (uPAR) binds inactive urokinase (pro-uPA), which is then
converted to active uPA. Active uPA proteolytically converts the inactive
zymogen plasminogen to active plasmin, which then breaks down ECM
components. Plasmin can also degrade the ECM indirectly through activation of
pro-matrix metalloproteinases (pro-MMPs). Figure taken from (99).
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Figure 6. MAPK Signaling. Mitogen-activated protein kinases (MAPK) are
involved in many cellular programs such as cell proliferation, cell differentiation,
cell movement, and cell death. MAPK signaling cascades are organized
hierarchically into three-tiered modules. MAPKs are phosphorylated and
activated by MAPK-kinases (MAPKKs), which in turn are phosphorylated and
activated by MAPKK-kinases (MAPKKKs). The MAPKKKs are in turn activated
by interaction with the family of small GTPases and/or other protein kinases,































Figure 7.a. Snail overexpression increases cell invasion in prostate cancer
cells. Prostate cancer cell line LNCaP, was stably transfected with empty vector
(Neo) or constitutively active Snail cDNA using lipofectamine 2000 were utilized
for cell invasion assays using the boyden chamber. LNCaP Neo and Snail, were
plated at 5xlO4 in culture inserts coated with matrigel. Cells that invaded through
were stained with crystal violet and counted Results are representative of3
independent experiments. Statistical Analysis was done using two-way ANOVA















Figure 7.b. Snail overexpression increases cell invasion in prostate cancer
cells. Prostate cancer cell line 22RV1 was stably transfected with empty vector
(Neo) or constitutively active Snail cDNA using lipofectamine 2000 were utilized
for cell invasion assays using the boyden chamber. 22RV1 Neo and Snail were
plated at 5xlO4 in culture inserts coated with matrigel. Cells that invaded through
were solubilized with Sorenson solution and optical density (OD) measured at
590 nm. Results are representative of 3 independent experiments. Statistical




Figure 7.c. Snail overexpression increases cell invasion in prostate cancer
cells. Prostate cancer cell line ARCaP was stably transfected with empty vector
(Neo) or constitutively active Snail cDNA using lipofectamine 2000 were utilized
for cell invasion assays using the boyden chamber. ARCaP Neo and Snail were
plated at 5xlO4 in culture inserts coated with matrigel. Cells that invaded through
were stained with crystal violet and either counted or solubilized with Sorenson
solution and optical density (OD) measured at 590 nm. Results are representative
of 3 independent experiments. Statistical Analysis was done using two-way
ANOVA or Student t-test (*p<0.05, **p<0.01, ***p<0.001).
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Figure 8.a. Snail increases uPA/uPAR levels and uPA activity in prostate
cancer cells. Total RNA was isolated from ARCaP Neo or ARCaP Snail cells.
Superarray analysis was performed utilizing GE arrays for cancer pathways. uPA
and uPAR RNA levels were up-regulated by Snail.
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Figure 8.b. Snail increases uPA/uPAR levels and uPA activity in prostate
cancer cells. Snail, uPA and uPAR protein expression was determined by
western blot analysis. Actin was utilized as the loading control. Results are




Figure 8.c. Snail increases uPA/uPAR levels and uPA activity in prostate
cancer cells. Secreted uPA activity was measured in conditioned media using
uPA activity assay. Results are representative of 3 independent experiments.
Statistical Analysis was done using two-way ANOVA or Student t-test (*p<0.05,
**p<0.01, ***p<0.001).
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Figure 9.a. Snail mediates cell invasion via uPAR. Transient transfection of control or
uPAR siRNA was performed on ARCaP Snail cells using Dharmafect 1 reagent, (a) uPA,
uPAR, and Snail expression was determined by western blot analysis. Actin was utilized






























Figure 9.b. Snail mediates cell invasion via uPAR. Transient transfection of control or
uPAR siRNA was performed on ARCaP Snail cells using Dharmafect 1 reagent. Invasion
through matrigel was tested on the cells treated with control siRNA and uPAR siRNA
using the boyden chamber. Results are representative of 3 independent experiments.
Statistical Analysis was done using two-way ANOVA or Student t-test (**p<0.01).
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Figure lO.a. ERK inhibition antagonizes Snail-mediated uPA activity and cell
invasion. Phospho- ERKl/2 (p-ERK) and total ERK 1/2 (t-ERK) expression was
determined by western blot analysis in LNCaP and ARCaP cells overexpressing
Snail. Actin was utilized as the loading control.
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Figure lO.b. ERK inhibition antagonizes Snail-mediated uPA activity and
cell invasion. ARCaP Snail cells were treated with UO126 MEK inhibitor for
various time points.. Phospho- ERK1/2 (p-ERK) and total ERK 1/2 (t-ERK)
expression was determined by western blot analysis in ARCaP cells
overexpressing Snail. Actin was utilized as the loading control.
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Figure lO.c. ERK inhibition antagonizes Snail-mediated uPA activity and
cell invasion. ARCaP Snail cells were treated with UO126 MEK inhibitor for
various time points. Secreted active uPA activity was measured in conditioned
media using uPA activity assay. Results are representative of 3 independent
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Figure lO.d. ERK inhibition antagonizes Snail-mediated uPA activity and
cell invasion. Invasion through matrigel was tested on ARCaP Snail cells without
and with UO126 for 24 hours using the boyden chamber. Results are
representative of 3 independent experiments. Statistical Analysis was done using
two-way ANOVA or Student t-test (*p<0.05).
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Figure 11
Figure 11. Proposed Model. Snail mediates invasion through uPA/uPAR and
MAPK signaling pathway in prostate cancer cells.
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